期刊
JOURNAL OF CLINICAL MEDICINE
卷 12, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/jcm12196265
关键词
aortic valve replacement; aortic bioprosthesis degeneration; sutureless aortic valve; transcatheter aortic valve
This study explores the clinical outcomes and technical aspects of using valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) to treat degenerated Perceval aortic bioprostheses. The results show that this treatment option is safe, effective, and associated with good clinical and hemodynamic results.
Background: Sutureless aortic bioprostheses are increasingly being used to provide shorter cross-clamp time and facilitate minimally invasive aortic valve replacement. As the use of sutureless valves has increased over the past decade, we begin to encounter their degeneration. We describe clinical outcomes and technical aspects in patients with degenerated sutureless Perceval (CorCym, Italy) aortic bioprosthesis treated with valve-in-valve transcatheter aortic valve replacement (VIV-TAVR). Methods: Between March 2011 and March 2023, 1310 patients underwent aortic valve replacement (AVR) with Perceval bioprosthesis implantation. Severe bioprosthesis degeneration treated with VIV-TAVR occurred in 32 patients with a mean of 6.4 +/- 1.9 years (range: 2-10 years) after first implantation. Mean EuroSCORE II was 9.5 +/- 6.4% (range: 1.9-35.1%). Results: Thirty of thirty-two (94%) VIV-TAVR were performed via transfemoral and two (6%) via transapical approach. Vascular complications occurred in two patients (6%), and mean hospital stay was 4.6 +/- 2.4 days. At mean follow-up of 16.7 +/- 15.2 months (range: 1-50 months), survival was 100%, and mean transvalvular pressure gradient was 18.7 +/- 5.3 mmHg. Conclusion: VIV-TAVR is a useful option for degenerated Perceval and appears safe and effective. This procedure is associated with good clinical results and excellent hemodynamic performance in our largest single-center experience.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据